Your browser doesn't support javascript.
loading
Two Malignancies With Differential Responses to Immune Checkpoint Inhibitors: A Case Report.
Han, Se Young; Jahagirdar, Balkrishna N; Dudek, Arkadiusz Z.
Afiliação
  • Han SY; University of Minnesota, Department of Medicine, Division of Hematology, Oncology, and Transplantation, Minneapolis, MN, U.S.A. seyoung@umn.edu.
  • Jahagirdar BN; Regions Cancer Care Center, HealthPartners, Saint Paul, MN, U.S.A.
  • Dudek AZ; University of Minnesota, Department of Medicine, Division of Hematology, Oncology, and Transplantation, Minneapolis, MN, U.S.A.
Anticancer Res ; 40(5): 2821-2826, 2020 May.
Article em En | MEDLINE | ID: mdl-32366429
ABSTRACT

BACKGROUND:

Immune checkpoint inhibitors (ICI) have changed the management of cancer dramatically. However, not all patients respond to ICI and their use places patients at a significant risk of immune-related adverse reactions. A few biomarkers including programmed death-1 receptor/programmed death-ligand 1 (PD-1/PD-L1), micro-satellite instability (MSI) status, and tumor mutational burden (TMB) have gained popularity as surrogates to predict responsiveness to ICI. CASE REPORT Herein, we report a 61-year-old male who was diagnosed with widespread metastatic adenocarcinoma and a discrete renal lesion. Most of the metastatic lesions, except the left kidney mass, responded to a combination immunotherapy. Subsequent left nephrectomy revealed a chromophobe renal cell carcinoma. With this multimodality approach, we were able to achieve a durable near complete remission in a patient with diffuse metastatic disease at diagnosis.

CONCLUSION:

In this report, we explored possible commercially available and experimental biomarkers in an attempt to explain his exceptional response.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Imunoterapia / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Imunoterapia / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article